Ghost Ileostomy in Advanced Ovarian Cancer A Reliable Option

Data de publicació:

Autors de IIS La Fe

Grups d'Investigació

Abstract

Objective: Diverting ileostomy (DI) has been proposed to reduce the incidence and consequences anastomotic leakage after bowel resection. In colorectal cancer treatment, ghost ileostomy (GI) has been proposed as an alternative to DI. Our objective was to report the results of GI associated with colorectal resection in the treatment of ovarian cancer. Materials and Methods: This is an observational pilot study performed in a single institution. The main objective sought was to report the results of GI associated with colorectal resection in the treatment of ovarian cancer: 26 patients were included. Results: Modified posterior exenteration was performed in 24 cases (92.3%) and rectum resection in the 2 cases of relapse (7.7%). After the main procedure GI was created, to check up the anastomosis status, a sequential postoperative rectoscopy was performed on postoperative day 5 +/- 1 (range, 4-7). Serum levels were monitored in first and third postoperative days just with a descriptive intention to establish its relationship with the rectoscopy findings. In 2 cases, rectoscopy demonstrated a leakage. During postoperative course, no other complication related with the GI or DI was observed. No case of clinical anastomotic leakage was found. Conclusions: To the extent of our knowledge, this is the first study in which GI has been performed for the treatment of patients with ovarian cancer. Ghost ileostomy represents a real option that may reduce the number of ileostomies performed in ovarian cancer without increasing the morbimortality. Ghost ileostomy presents the advantages of DI while avoiding its drawbacks. It also seems to be a safe, feasible, and reproducible technique that does not add significant costs to the surgery.

Dades de la publicació

ISSN/ISSNe:
1048-891X, 1525-1438

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER  LIPPINCOTT WILLIAMS & WILKINS

Tipus:
Article
Pàgines:
1418-1426
PubMed:
29923854
Factor d'Impacte:
0,760 SCImago
Quartil:
Q2 SCImago

Cites Rebudes en Web of Science: 9

Documents

  • No hi ha documents

Mètriques

Filiacions mostrar / ocultar

Keywords

  • Ovarian cancer; Colorectal resection; Ghost ileostomy; Leakage; Diverting ileostomy

Campos d'Estudi

Projectes associats

ESTUDIO DE LA ENFERMEDAD METASTASICA EN EL TEJIDO OVARICO CRIOPRESERVADO DE MUJERES CON CANCER DE MAMA

Investigador Principal: ANTONIO PELLICER MARTÍNEZ

PI08/90483 . INSTITUTO DE SALUD CARLOS III . 2009

Ileostomía vistual combinada con endoscopia postoperatoria ebn cáncer de recto con escisión total mesorrectal. ¿podemos evitar estomas innecesarios? estudio prospectivo observacional multicénctrico.

Investigador Principal: BLAS FLOR LORENTE

PI17/00863 . INSTITUTO DE SALUD CARLOS III . 2018

"TIMing Evaluation of Stoma closure” Cierre precoz vs tardío del estoma derivativo tras cirugía de cáncer de recto.

Investigador Principal: MATTEO FRASSON

2018_0078_CRC_FRASSON . ASOCIACIÓN ESPAÑOLA DE COLOPROCTOLOGÍA (AECP) . 2018

Trocar multisensor para cirugía laparoscópica con presión de pneumoperitoneo individualizada

Investigador Principal: ÓSCAR DÍAZ CAMBRONERO

INNVAL10/18/056 . AGENCIA VALENCIANA DE LA INNOVACION (AVI) . 2018

SEGURIDAD Y RENDIMIENTO DEL DISPOSITIVO DE CAPTURA DE CÉLULAS TUMORALES METASTÁSICAS EN PACIENTES CON CÁNCER OVÁRICO AVANZADO.

Investigador Principal: SANTIAGO DOMINGO DEL POZO

MTRAP-2016-01 . 2017

INDIVIDUALIZED PERIOPERATIVE HEMODYNAMIC GOAL-DIRECTED THERAPY IN MAJOR ABDOMINAL SURGERY (IPEGASUS-TRIAL).

Investigador Principal: ÓSCAR DÍAZ CAMBRONERO

IPEGASUS . 2017

SENTOV: GANGLIO CENTINELA EN CÁNCER DE OVARIO EN ESTADIO INICIAL.

Investigador Principal: VÍCTOR LAGO LEAL

SENTOV . 2017

MU OPIOID RECEPTOR 1 (MOR-1) EXPRESSION IN COLORECTAL CANCER AND DISEASE-FREE SURVIVAL RELATIONSHIP (MOROCCO). FIVE-YEAR FOLLOW-UP.

Investigador Principal: ÓSCAR DÍAZ CAMBRONERO

ODC-MOR-2018-01

ENSAYO CLÍNICO FASE II ALEATORIZADO, ABIERTO Y MULTICÉNTRICO, PARA DETERMINAR LA TOXICIDAD Y EFICACIA DE QUIMIOTERAPIA PRE-QUIRÚRGICA CON O SIN BEVACIZUMAB EN PACIENTES CON CÁNCER DE OVARIO AVANZADO.

Investigador Principal: ANA SANTABALLA BERTRÁN

GEICO-1205 . 2014

PRESIÓN INDIVIDUALIZADA DE INSUFLACIÓN DEL PNEUMOPERITONEO EN CIRUGÍA LAPAROSCÓPICA COLORECTAL FRENTE A TERAPIA ESTÁNDAR.

Investigador Principal: ÓSCAR DÍAZ CAMBRONERO

IPPCOLLAPSE-II . 2016

ENSAYO CLÍNICO FASE III, MULTICÉNTRICO ALEATORIZADO PARA COMPARAR LA EFICACIA DE LA ADICIÓN DE CIRUGÍA DE CITORREDUCCIÓN A LA QUIMIOTERAPIA FRENTE A LA QUIMIOTERAPIA EXCLUSIVA EN EL CÁNCER DE OVARIO RECIDIVADO SENSIBLE A PLATINO.

Investigador Principal: ANA SANTABALLA BERTRÁN

GEI-CIR-2011-01

Compartir la publicació